X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4161) 4161
Book Review (403) 403
Publication (121) 121
Conference Proceeding (8) 8
Magazine Article (3) 3
Book / eBook (1) 1
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3915) 3915
index medicus (3878) 3878
female (2709) 2709
male (2585) 2585
middle aged (2458) 2458
vinblastine - administration & dosage (2315) 2315
adult (2282) 2282
antineoplastic combined chemotherapy protocols - therapeutic use (2213) 2213
aged (2085) 2085
oncology (2054) 2054
antineoplastic combined chemotherapy protocols - adverse effects (1860) 1860
vinblastine - adverse effects (1818) 1818
vinblastine - analogs & derivatives (1549) 1549
chemotherapy (1409) 1409
cisplatin - administration & dosage (1067) 1067
vinblastine (998) 998
treatment outcome (983) 983
vinblastine - therapeutic use (909) 909
lung neoplasms - drug therapy (782) 782
vinorelbine (757) 757
cancer (750) 750
cisplatin (703) 703
doxorubicin - administration & dosage (655) 655
neoplasm staging (647) 647
adolescent (632) 632
bleomycin - administration & dosage (628) 628
cisplatin - adverse effects (619) 619
hodgkin disease - drug therapy (608) 608
carcinoma, non-small-cell lung - drug therapy (601) 601
drug administration schedule (599) 599
antineoplastic combined chemotherapy protocols - administration & dosage (567) 567
breast neoplasms - drug therapy (541) 541
combined modality therapy (519) 519
bleomycin - adverse effects (516) 516
deoxycytidine - analogs & derivatives (509) 509
aged, 80 and over (480) 480
survival rate (471) 471
doxorubicin - adverse effects (450) 450
survival analysis (447) 447
disease-free survival (446) 446
abridged index medicus (445) 445
deoxycytidine - administration & dosage (431) 431
antineoplastic agents - adverse effects (413) 413
therapy (398) 398
prognosis (385) 385
doxorubicin (384) 384
trial (374) 374
retrospective studies (351) 351
follow-up studies (350) 350
neoplasm metastasis (348) 348
vincristine - administration & dosage (338) 338
lung neoplasms - pathology (333) 333
dacarbazine - administration & dosage (330) 330
antineoplastic agents - therapeutic use (329) 329
pharmacology & pharmacy (326) 326
gemcitabine (313) 313
paclitaxel (307) 307
antineoplastic agents, phytogenic - adverse effects (302) 302
care and treatment (300) 300
carcinoma, non-small-cell lung - pathology (298) 298
etoposide - administration & dosage (296) 296
methotrexate (290) 290
drug therapy, combination (289) 289
dose-response relationship, drug (286) 286
survival (285) 285
urinary bladder neoplasms - drug therapy (284) 284
breast neoplasms - pathology (280) 280
carcinoma (280) 280
remission induction (280) 280
antineoplastic agents, phytogenic - administration & dosage (277) 277
prednisone - administration & dosage (276) 276
testicular neoplasms - drug therapy (275) 275
radiotherapy (271) 271
methotrexate - administration & dosage (266) 266
paclitaxel - administration & dosage (265) 265
vincristine - adverse effects (264) 264
combination (261) 261
hematology (261) 261
time factors (260) 260
cyclophosphamide - administration & dosage (259) 259
medicine & public health (256) 256
procarbazine - administration & dosage (250) 250
dacarbazine - adverse effects (248) 248
combination chemotherapy (247) 247
prospective studies (246) 246
carcinoma, transitional cell - drug therapy (244) 244
bleomycin (243) 243
hodgkin disease - radiotherapy (243) 243
neutropenia - chemically induced (242) 242
animals (240) 240
carboplatin (236) 236
antineoplastic agents - administration & dosage (235) 235
breast cancer (230) 230
docetaxel (230) 230
deoxycytidine - adverse effects (222) 222
child (221) 221
infusions, intravenous (221) 221
toxicity (219) 219
drug evaluation (218) 218
antineoplastic agents, phytogenic - therapeutic use (217) 217
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3737) 3737
French (102) 102
Japanese (90) 90
German (78) 78
Chinese (38) 38
Russian (37) 37
Spanish (28) 28
Italian (17) 17
Polish (15) 15
Czech (6) 6
Hebrew (4) 4
Portuguese (3) 3
Danish (2) 2
Dutch (2) 2
Hungarian (2) 2
Serbian (2) 2
Bulgarian (1) 1
Croatian (1) 1
Romanian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cell Cycle, ISSN 1538-4101, 05/2012, Volume 11, Issue 9, pp. 1851 - 1861
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 5, pp. 592 - 598
Purpose To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive... 
2ND CANCER-RISK | RANDOMIZED-TRIALS | ONCOLOGY | DNA TOPOISOMERASE-II | ALKYLATING-AGENTS | COMBINED-MODALITY TREATMENT | DISEASE | MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROMES | CHEMOTHERAPY | ACUTE PROMYELOCYTIC LEUKEMIA | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Leukemia, Myeloid, Acute - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Mechlorethamine - adverse effects | Male | Risk | Leukemia, Myeloid, Acute - etiology | Incidence | Hodgkin Disease - radiotherapy | Melphalan - adverse effects | Chemotherapy, Adjuvant - adverse effects | Radiotherapy, Adjuvant - adverse effects | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Adult | Female | Retrospective Studies | Databases, Factual | Radiotherapy Dosage | Prednisone - adverse effects | Drug Administration Schedule | California - epidemiology | Clinical Trials as Topic | Bleomycin - adverse effects | Academic Medical Centers | Myelodysplastic Syndromes - epidemiology | Myelodysplastic Syndromes - etiology | Neoplasms, Second Primary - epidemiology | Neoplasms, Second Primary - etiology | Methotrexate - adverse effects | Procarbazine - adverse effects | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus | Hema14 | Hema13 | Hema12 | ORIGINAL REPORTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 2, pp. 231 - 239
Purpose To optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during survivorship, information on the impact of chemotherapy... 
INHIBIN-B | PRESERVATION | OUTCOME MEASURE | OVARIAN RESERVE | ONCOLOGY | TERM FOLLOW-UP | DISEASE | FEMALE CANCER SURVIVORS | ANTI-MULLERIAN HORMONE | CHEMOTHERAPY | SERUM MARKER | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Gonadotropin-Releasing Hormone - analogs & derivatives | Fertility - physiology | Fertility Preservation | Young Adult | Vinblastine - adverse effects | Follicle Stimulating Hormone - blood | Hodgkin Disease - drug therapy | Oligospermia - epidemiology | Vincristine - administration & dosage | Adult | Female | Gonadotropin-Releasing Hormone - therapeutic use | Hodgkin Disease - physiopathology | Inhibins - blood | Menstrual Cycle - drug effects | Testosterone - blood | Menstrual Cycle - physiology | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Survivors | Etoposide - administration & dosage | Ovary - physiology | Hodgkin Disease - epidemiology | Bleomycin - administration & dosage | Bleomycin - adverse effects | Germany - epidemiology | Randomized Controlled Trials as Topic | Pregnancy | Testis - physiology | Hodgkin Disease - blood | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 684 - 691
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 5, pp. 399 - 408
In patients with limited-stage Hodgkin's disease, ABVD chemotherapy alone resulted in a higher rate of long-term (12-year) survival than either radiation... 
CLINICAL-PRACTICE GUIDELINES | MEDICINE, GENERAL & INTERNAL | INTERGROUP TRIAL | RANDOMIZED-TRIALS | DISEASE | DOXORUBICIN | VINBLASTINE | BLEOMYCIN | FIELD RADIOTHERAPY | CHEMOTHERAPY | COOPERATIVE-ONCOLOGY-GROUP | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Follow-Up Studies | Dacarbazine - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Neoplasms, Second Primary - mortality | Radiotherapy - adverse effects | Vinblastine - therapeutic use | Cause of Death | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Treatment Outcome | Combined Modality Therapy | Bleomycin - adverse effects | Hodgkin Disease - complications | Heart Diseases - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Neoplasm Staging | Doxorubicin - adverse effects | Drugs | Usage | Care and treatment | Vinblastine | Patient outcomes | Product/Service Evaluations | Radiotherapy | Doxorubicin | Dacarbazine | Bleomycin | Dosage and administration | Drug therapy, Combination | Drug therapy | Hodgkin's disease | Medical research | Clinical trials | Radiation therapy | Lymphoma | Survival | Patients | Chemotherapy | Lymphomas | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1348 - 1356
Journal Article
Journal of clinical endocrinology and metabolism, ISSN 0021-972X, 2007, Volume 92, Issue 10, pp. 3869 - 3874
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 33, pp. 4117 - 4123
Purpose Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral... 
PROGNOSTIC-FACTORS | ONCOLOGY | INFECTION HD-HIV | ACTIVE ANTIRETROVIRAL THERAPY | DISEASE | RANDOMIZED-TRIAL | STANFORD-V | STEM-CELL TRANSPLANTATION | PATIENTS PTS | IMMUNODEFICIENCY | CHEMOTHERAPY | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Hodgkin Disease - pathology | Humans | Lymphoma, AIDS-Related - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Hodgkin Disease - radiotherapy | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Lymphoma, AIDS-Related - drug therapy | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | HIV Infections - complications | Lymphoma, AIDS-Related - radiotherapy | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2010, Volume 151, Issue 2, pp. 159 - 166
Peripheral T-Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission and survival rates than B-cell... 
cyclophosphamide | clinical trials | vincristine | doxorubicin | prednisone (CHOP) | T-cell lymphoma | NON-HODGKINS-LYMPHOMAS | CLASSIFICATION | IFOSFAMIDE | CHEMOTHERAPY | TRANSPLANTATION | ETOPOSIDE | THERAPY | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Young Adult | Vinblastine - adverse effects | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Ifosfamide - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Adolescent | Survival Analysis | Cisplatin - adverse effects | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Anthracyclines | Cyclophosphamide | Corticosteroids | Etoposide | Clinical trials | Product development | Prednisone | Non-Hodgkin's lymphomas | T cells | double prime B-cell lymphoma | Cell survival | Vinblastine | Ifosfamide | Toxicity | Doxorubicin | Survival | Vincristine | Cisplatin | Dacarbazine | Bleomycin | Remission | double prime T-cell lymphoma | Anaplastic large-cell lymphoma | expressed sequence tags | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 07/2012, Volume 23, Issue 7, pp. 1818 - 1825
In the HD14 trial, 2x BEACOPP(escalated) + 2x ABVD (2 + 2) has improved the primary outcome. Compared with 4x ABVD, this benefit might be compromised by more... 
Chemotherapy | GnRH analogues | Fertility | Ovarian reserve | Hodgkin lymphoma | fertility | ovarian reserve | ANTI-MULLERIAN HORMONE | chemotherapy | CANCER | PRESERVATION | WOMEN | THERAPY | ONCOLOGY | CLINICAL-TRIALS | DISEASE | ORAL-CONTRACEPTIVES | OVARIAN-FUNCTION | Doxorubicin - therapeutic use | Multivariate Analysis | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Gonadotropin-Releasing Hormone - analogs & derivatives | Cyclophosphamide - therapeutic use | Young Adult | Bleomycin - therapeutic use | Menopause - drug effects | Vinblastine - adverse effects | Fertility - drug effects | Follicle Stimulating Hormone - blood | Hodgkin Disease - drug therapy | Adult | Female | Ovary - drug effects | Gonadotropin-Releasing Hormone - therapeutic use | Menstrual Cycle - drug effects | Anti-Mullerian Hormone - blood | Etoposide - adverse effects | Prednisone - adverse effects | Survivors | Etoposide - therapeutic use | Logistic Models | Bleomycin - adverse effects | Randomized Controlled Trials as Topic | Pregnancy | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Ovary - physiopathology | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2010, Volume 363, Issue 7, pp. 640 - 652
Journal Article